Excessive tissue fibrosis in various lung diseases contributes to decline in lung function and subsequent morbidity and mortality. Mechanisms involve complex networks of molecules such as cytokines that are not clearly worked out in conditions such as Idiopathic pulmonary fibrosis (IPF). Furthermore, pulmonary virus infection has been linked to exacerbations of IPF. Previous studies have demonstrated that transient pulmonary over-expression of Oncostatin M (OSM) leads to increased extracellular matrix (ECM) accumulation, Th2-skewed cytokines and Arg1+ M2-like macrophage accumulation in mouse models. OSM can also robustly induce interleukin-33 (IL-33), an IL1 family cytokine or alarmin, both in vivo and in vitro mouse lung systems. Since others have shown that soluble IL-33 exacerbates bleomycin-induced lung fibrosis in mouse models and is associated with Th2-type lung diseases, IL-33 may mediate OSM effects on ECM and Arg1+ macrophage-like cell accumulation. The main hypothesis in this thesis is that OSM can induce IL-33 expression and Arg1+ cells, that OSM can potentiate IL-33 release from virally-infected epithelial cells, and that OSM can prime lungs to subsequent influenza infection and exacerbate pathology. Results demonstrated that OSM induced robust up-regulation of pulmonary IL-33 and Arg1 mRNA and protein expression in vivo, in comparison to another gp130 cytokine, IL-6. However, IL-6 was required for OSM-induced arginase-1 expression in vivo, but not IL-33 expression in vivo. OSM-induced Arg1 expression was also dependent upon IL-33 presence as demonstrated in IL-33-/- animals. This finding implicates a role for both IL-33 and IL-6 in mediating OSM-induced Arg1+ macrophage-like cell accumulation within the lung. Additionally, results showed that a respiratory Influenza A virus infection in vivo alone induced a time-dependent increase in OSM and IL-33 (Day 4), however reduced IL-33 by 7-days post-infection. Influenza infection in AdOSM-primed mice and led to decreased IL-33 expression and eosinophilic infiltration within the lung 5-days post-influenza infection. Collectively, these results demonstrate that OSM can drive Th2-associated pathology correlated to increased IL-33 and Arg1 expression. Contrary to expectations, influenza A virus infection led to a reduction in OSM-induced Th2-phenotype in vivo. Further exploration into the OSM-IL-33 pathway will provide insight into innate immune mechanisms of lung inflammation, virus infection and control of ECM accumulation. / Thesis / Master of Science (MSc)

Le dysfonctionnement endothélial et le dérèglement du système immunitaire sont les deux principaux mécanismes physiopathologiques responsables de la fibrose de la peau et des organes internes dans la sclérodermie systémique (ScS). La pneumopathie interstitielle diffuse (PID) est devenue la principale cause de mortalité de la maladie. L'inflammation pulmonaire est la conséquence de l'activation du système immunitaire, qui stimule la NO synthase inductible (NOS-2) et augmente la production alvéolaire de monoxyde d'azote (NO). L'augmentation de la concentration alvéolaire de NO (CANO) est significativement corrélée à la sévérité de la PID chez les patients atteints de ScS. L'augmentation de la CANO est liée à l'effet inducteur du sérum des malades sur la prolifération des fibroblastes pulmonaires et leur différentiation en myofibroblastes, faisant ainsi le lien biologique entre l'inflammation alvéolaire et la fibrose pulmonaire dans la ScS. Nous avons ensuite testé la valeur prédictive de la CANO dans la détérioration de la PID. Les patients ayant une CANO supérieure à 5,3 ppb présentent un risque élevé (> 6 fois) de voir survenir l'aggravation de la fibrose pulmonaire ou le décès (évènement combiné) par rapport à ceux qui ont une CANO inférieure ou égale à 5,3 ppb. Une valeur de CANO supérieure ou égale à 8,5 ppb permet de détecter les patients avec un risque de 90% de survenue d'évènement combiné dans les trois ans. Ces patients pourraient alors bénéficier d'un traitement approprié précoce. Nous avons évalué l'inflammation pulmonaire dans deux modèles murins de fibrose pulmonaire induite par l'acide hypochloreux et la bléomycine, par la mesure non-invasive du NO expiré (FENO). Le pic d'augmentation de FENO se situe 4 semaines après le début des injections, et précède la fibrose pulmonaire, qui ne devient significative qu'à partir de 6 semaines d'intoxication. L'augmentation de la FENO est liée à l'augmentation de l'expression de la NOS-2 aussi bien aux niveaux des bronches qu'aux niveaux des alvéoles. Enfin, la forte production de NO constatée provoque un effet délétère direct sur le tissu pulmonaire attesté par la présence de 3-nitrotyrosines, marqueurs du stress nitrosatif.Mots-clés: sclérodermie systémique, pneumopathie interstitielle diffuse, monoxyde d'azote, physiopathologie. / Summary not transmitted

La Radiothérapie occupe la deuxième place dans la liste de traitement du cancer le plus important après chirurgie. Le progrès technique récent, comme la radiothérapie avec modulation d'intensité (IMRT) ou la radiothérapie guidée par l'image (IGRT), en combinaison avec de nouveaux médicaments à action spécifique tels que les anticorps monoclonaux, sont une garantie d'augmentation de l'index thérapeutique. Cependant, la radiothérapie peut provoquer un’ altération du processus normal de réparation et d'induire le développement d'un cadre de fibrose dans un sous-ensemble de patients sensibles et dans les survivants à long terme au cancer. La principale caractéristique de la fibrose radio-induit est l'accumulation excessive et anormale de collagène composé principalement des éléments fibrillaire et immatures de la matrice extracellulaire (ECM).Les organes qui peuvent être touchés par ce phénomène sont le foie, la peau, les intestins, les reins et les poumons. D'un point de vue clinique, la fibrose peut être considérée comme une condition irréversible, sans solution. Nous et d'autres ont récemment montré que, outre l'activation de la TGF-β/Smad canonique, d'autres voies sont activées dans les tissus fibreux tels que la cascade de signalisation intracellulaire Rho/ROCK. Fait intéressant, la façon dont Rho/ROCK semble spécifiquement activé dans la fibrose intestinale radio-induite, fournis une justification pour un stratégie anti-fibrotique ciblé. L’ inhibition pharmacologique de Rho avec les statines, en fait, est en mesure de prévenir et même inverser les phénomènes de fibrose post-actinique intestinale.Avec ces prémisses, dans nos études, nous avons montré le rôle des statines (Simvastatine et Pravastatine) et d'un inhibiteur spécifique de ROCK (Y-27632) dans un modèle murin de fibrose pulmonaire obtenue avec une approche pharmacologique (Bléomycine - BLM) . Par la suite, nous avons développé un modèle de fibrose pulmonaire induite par l'irradiation complet du thorax et évalué la réponse à l'administration de la Pravastatine. La confirmation de la participation de la voie Rho/ROCK/CTGF dans la fibrose pulmonaire a été montré par immunohistochimie: le traitement à la Pravastatine normalise l'expression de trois marqueurs: RhoB, TGFβ-RII et CTGF.Après, dans deux modèles de fibrose radio-induite (intestinal et pulmonaire), nous avons analysé, grâce à l’immunohistochimie, les mécanismes sous-jacents l'action antifibrotique de la Pravastatine via l’axe MMP2-TIMP2. Très intéressant, quand la pravastatine a été administré à titre préventif ou curatif, nous avons trouvé un impact différent sur la fibrolyse.Enfin, in vitro, nous avons étudié par zymographie l'expression des gélatinases (MMP2 et MMP9) dans des cultures primaires des fibroblastes pulmonaire murins exposées à différentes doses de rayonnement et de Pravastatine. Le métalloprotéases semble être à son tour impliquée dans les mécanismes pro-fibrolytiques induits par les statines.Dans notre modèle animal de fibrose pulmonaire, la Pravastatine est capable d'inverser le processus fibrotique et les métalloprotéases semblent être impliqués à leur tour, in vivo et in vitro, dans les mécanismes pro-fibrolyse induits par le médicament.La multiplicité des acteurs impliqués dans la physiopathologie de lésions fibrotiques explique pourquoi la mise en place d'une stratégie thérapeutique efficace est si complexe. La recherche dans les processus mécaniques de dommages aux tissus normaux ont ouvert la voie à de nouvelles approches thérapeutiques. Ces nouvelles cibles comprennent la réduction de l’inflammation, de l'activation vasculaire et de la thrombose, ainsi que la découverte de nouvelles cibles moléculaires. Il existe une variété de modèles précliniques et des stratégies efficaces, mais de nombreux efforts doivent être déployés pour atteindre l'objectif difficile de protéger les tissus normaux des effets secondaires de la radiothérapie. / Radiotherapy is the second most important treatment modality after surgery in the treatment of cancer. Recent technical advancements, such as intensity-modulated radiation therapy (IMRT) or image-guided radiation therapy (IGRT), combined with new targeted drugs have significant promise for therapeutic outcome. However radiation treatment could result in disabling normal tissue injury and in the development of progressive fibrosis in a subset of sensitive patients and in long-term cancer survivors. The main feature of tissue fibrosis is excessive accumulation of abnormal and cross-linked collagen mainly composed of fibrillar and immature extracellular matrix (ECM) components.The organs that can be affected by this phenomenon are liver, skin, intestine, kidneys and lungs. From a clinical point of view, fibrosis can be seen as an irreversible condition, without solution. We and others recently showed that beside the activation of the canonical TGF-β/Smad pathway, other intracellular signaling cascades including the Rho/ROCK pathway are switched on in fibrotic tissues. Interestingly, the Rho/ROCK pathway seems differentially activated in radiation-induced intestinal fibrosis, thereby providing a rationale for a specific, targeted anti-fibrotic strategy. Pharmacological inhibition of Rho using statins indeed prevent and even reverse intestinal radiation fibrosis.In our studies, we showed the role of Statin (Pravastatin e Simvastatin) and a specific inhibitor ROCK inhibitors (Y-27632) in a mice model of pulmonary induced-fibrosis obtained by a pharmacological approach (Bleomycin – BLM). Indeed, we developed a model of lung fibrosis by complete irradiation of chest and tested Pravastatin action. Confirmation of the involvement of Rho/ROCK/CTGF pathway in lung fibrosis are shown by immunohistochemistry: Pravastatin-treament normalized the expression of three markers: RhoB, TGF-RII and CTGF.Then, in models of radiation induced gut and lung fibrosis, we analysed, from a immunohistological point of view, the underlying mechanisms of the antifibrotic action of Pravastatin via MMP2-TIMP2 axis. Interestingly we found a different impact on fibrolysis when Pravastatin was administered preventively or curatively.Finally, in vitro, we investigate by zymography the expression of Gelatinases (MMP2 and MMP9) in primary lung fibroblasts cultures exposure at the different radiation and Pravastatin doses. Metalloproteases would appear to be in turn involved in pro-fibrolytic mechanisms induced by statin.The multiplicity of actors involved in the pathogenesis of fibrotic lesions explains why the definition of an effective therapeutic strategy is so complex.Researches in mechanistic processes of normal tissue damage paved the way for new therapeutic approaches. These new targets include reduction of vascular activation, inflammation and thrombosis and new molecular targets definition. Effective strategies are multiple on preclinical models, but numerous efforts have to be made to achieve the complicated goal of protection of normal tissues from the side effects of radiation therapy. / La radioterapia è la seconda modalità di trattamento più importante dopo chirurgia neltrattamento delle neoplasie. I recenti progressi tecnici, come la terapia ad intensità modulata(IMRT) o l’image-guided radioterapia (IGRT), in combinazione con nuovi farmaci ad azionemirata come gli anticorpi monoclonali, costituiscono ulteriore garanzia di incrementodell’indice terapeutico. Tuttavia il trattamento radiante può causare un’alterazione delnormale processo di riparazione e indurre lo sviluppo di un quadro di fibrosi in unsottogruppo di pazienti sensibili e nei lungo-sopravviventi al cancro. La caratteristicacardinale della fibrosi radioindotta è l’eccessivo ed anomalo accumulo di collagene compostoprincipalmente di componenti fibrillari e immature della matrice extracellulare (ECM).Gli organi che possono essere interessati da questo fenomeno sono fegato, pelle,intestino, reni e polmoni. Da un punto di vista clinico, la fibrosi può essere vista come unacondizione irreversibile, senza soluzione. Noi ed altri recentemente abbiamo mostrato cheaccanto alla attivazione della via canonica TGF-β/Smad, altre vie vengono attivate nei tessutifibrotici come la cascata di segnalazione intracellulare della via Rho/ROCK. Interessantenotare che la via Rho/ROCK sembra specificatamente attivata nella radiazione indotta fibrosiintestinale, fornendo così una spiegazione razionale per una specifica, mirata strategia antifibrotica.L'inibizione farmacologica di Rho con le statine infatti è in grado di prevenire eaddirittura invertire i fenomeni di fibrosi intestinale post-attinica.Grazie a queste premesse, nei nostri studi, abbiamo mostrato il ruolo delle statine(Pravastatina e Simvastatina) e di uno specifico inibitore di ROCK (Y-27632) in un modellomurino di fibrosi polmonare indotta ottenuto con un approccio farmacologico (bleomicina -BLM). In seguito, abbiamo sviluppato un modello di fibrosi polmonare indottadall’irradiazione completa del torace e valutata la risposta alla somministrazione dellaPravastatina. In questo modello ed in un modello di fibrosi intestinale indotto da radiazioni,abbiamo analizzato, da un punto di vista immunoistologico, i meccanismi sottostanti l'azione9antifibrotica della pravastatina e il ruolo delle metalloproteasi (MMP2 e TIMP2). Infine, invitro, abbiamo indagato, mediante zimografia, l'espressione delle gelatinasi (MMP2 e MMP9)in culture primarie di fibroblasti polmonari murini esposti a differenti dosi di radiazione epravastatina.Nel nostro modello animale di fibrosi polmonare, la Pravastatina è in grado di renderereversibile il processo fibrotico e le metalloproteasi parrebbero essere a loro volta coinvolte,in vivo and in vitro, nei meccanismi pro-fibrolitici indotti dal farmaco.La molteplicità di attori coinvolti nella patogenesi delle lesioni fibrotiche spiegaperché la definizione di una strategia terapeutica efficace è così complessa. Ricerche neiprocessi meccanicistici di danno ai tessuti normali hanno aperto la strada a nuovi approcciterapeutici. Questi nuovi obiettivi comprendono la riduzione dell’ attivazione vascolare,dell'infiammazione e della trombosi, oltre alla definizione di nuovi target molecolari. Esistonomolteplici ed efficaci strategie su modelli preclinici, ma numerosi sforzi devono essere fattiper raggiungere il complicato obiettivo di proteggere i tessuti normali dagli effetti collateralidella radioterapia.

Radiotherapy is the second most important treatment modality after surgery in the treatment of cancer. Recent technical advancements, such as intensity-modulated radiation therapy (IMRT) or image-guided radiation therapy (IGRT), combined with new targeted drugs have significant promise for therapeutic outcome. However radiation treatment could result in disabling normal tissue injury and in the development of progressive fibrosis in a subset of sensitive patients and in long-term cancer survivors. The main feature of tissue fibrosis is excessive accumulation of abnormal and cross-linked collagen mainly composed of fibrillar and immature extracellular matrix (ECM) components.The organs that can be affected by this phenomenon are liver, skin, intestine, kidneys and lungs. From a clinical point of view, fibrosis can be seen as an irreversible condition, without solution. We and others recently showed that beside the activation of the canonical TGF-β/Smad pathway, other intracellular signaling cascades including the Rho/ROCK pathway are switched on in fibrotic tissues. Interestingly, the Rho/ROCK pathway seems differentially activated in radiation-induced intestinal fibrosis, thereby providing a rationale for a specific, targeted anti-fibrotic strategy. Pharmacological inhibition of Rho using statins indeed prevent and even reverse intestinal radiation fibrosis.In our studies, we showed the role of Statin (Pravastatin e Simvastatin) and a specific inhibitor ROCK inhibitors (Y-27632) in a mice model of pulmonary induced-fibrosis obtained by a pharmacological approach (Bleomycin - BLM). Indeed, we developed a model of lung fibrosis by complete irradiation of chest and tested Pravastatin action. Confirmation of the involvement of Rho/ROCK/CTGF pathway in lung fibrosis are shown by immunohistochemistry: Pravastatin-treament normalized the expression of three markers: RhoB, TGF-RII and CTGF.Then, in models of radiation induced gut and lung fibrosis, we analysed, from a immunohistological point of view, the underlying mechanisms of the antifibrotic action of Pravastatin via MMP2-TIMP2 axis. Interestingly we found a different impact on fibrolysis when Pravastatin was administered preventively or curatively.Finally, in vitro, we investigate by zymography the expression of Gelatinases (MMP2 and MMP9) in primary lung fibroblasts cultures exposure at the different radiation and Pravastatin doses. Metalloproteases would appear to be in turn involved in pro-fibrolytic mechanisms induced by statin.The multiplicity of actors involved in the pathogenesis of fibrotic lesions explains why the definition of an effective therapeutic strategy is so complex.Researches in mechanistic processes of normal tissue damage paved the way for new therapeutic approaches. These new targets include reduction of vascular activation, inflammation and thrombosis and new molecular targets definition. Effective strategies are multiple on preclinical models, but numerous efforts have to be made to achieve the complicated goal of protection of normal tissues from the side effects of radiation therapy.

[Truncated abstract] Fibrosis is a feature of many pulmonary conditions, including idiopathic pulmonary fibrosis (IPF), which is characterised by the accumulation of fibroblasts/myofibroblasts and excessive deposition of collagen. IPF is a disease of unknown aetiology that is unresponsive to current therapy and is typically fatal. The inflammatory cytokine interleukin (IL)-6 is elevated in patients with IPF and recent studies have shown that IL-6-induced signalling is altered in lung fibroblasts from patients with IPF. IL-6 belongs to the gp130 cytokine family, which is a group of ten structurally related cytokines, that all require the membrane bound glycoprotein gp130 to activate intracellular signalling pathways. Gp130 activates intracellular signalling through the Shp2-ERK1/2 and STAT1/3 pathways to mediate cellular activities. This thesis tests the hypothesis that gp130-mediated signalling is dysregulated in the development and progression of pulmonary fibrosis. To address this hypothesis, I assessed the role of gp130-mediated signalling in a mouse model of bleomycin-induced lung fibrosis. This thesis utilised two novel gp130 mutant mice strains with directed and enhanced gp130-mediated Shp2-ERK1/2 (gp130¿STAT/¿STAT) or STAT1/3 (gp130757F/757F) signalling. I observed complete protection from fibrosis in gp130¿STAT/¿STAT mice up to 60 days after bleomycin treatment and profound fibrosis in gp130757F/757F mice compared to wt controls. The enhanced fibrosis observed in gp130757F/757F mice was diminished by monoallelic deletion of STAT3 (gp130757F/757F;STAT3+/-), identifying gp130-STAT3 signalling as a novel promoter of lung fibrosis. ... In addition, IL-6/11 activation of gp130-mediated signalling modulated transforming growth factor (TGF)-ß-induced effects on adult fibroblast proliferation and myofibroblast differentiation. Interaction between IL-6/11 and TGF-ß1 on fibroblast proliferation was dependent on both the gp130-ERK1/2 and gp130-STAT1/3 pathways. Loss of either pathway abrogated the effects of IL-6 and IL-11 on TGF-ß1- 4 induced fibroblast proliferation. However, it was clear that gp130-STAT3 signalling inhibited TGF-ß1-induced myofibroblast differentiation of primary lung fibroblasts. The inhibition of myofibroblast differentiation was associated with gp130-STAT3 dependent inhibition of TGF-ß1-induced Smad3 phosphorylation. These results indicate that IL-6 and IL-11 promote myofibroblastic differentiation of lung fibroblasts, while gp130-STAT3 signalling inhibits TGF-ß1-induced Smad3 phosphorylation and myofibroblastic differentiation of lung fibroblasts While the pathogenesis of IPF is unknown, it is believed that excessive collagen deposition, aberrant fibroblast behaviour and an inflammatory response are critical to the progression of this disease. It has been shown here that IL-6 family cytokines mediate the development and progression of bleomycin-induced lung fibrosis by increasing collagen synthesis, fibroblast proliferation, myofibroblast differentiation and inflammation through gp130-STAT3 signalling. This thesis has demonstrated that differential activation of cytoplasmic signalling pathways by a membrane bound receptor can have a profound effect on pulmonary responses to injury. Furthermore, this thesis is the first study to identify the gp130-STAT3 pathway as a therapeutic target in the treatment of IPF.

<p>IPF is a respiratory condition of unknown etiology that has poor survival prognosis. The stiffening of the lung associated with this condition is attributed to the irreversible turnover of healthy lung tissue into scar tissue, which affects gas exchange and can eventually lead to organ failure. Numerous studies have implicated the pro-fibrogenic growth factor TGF-β, through activation of the SMAD2/3 pathway, as a central mediator in the pathology of this condition. However, other cytokines, including members of the IL-6/gp130 family such as OSM, and other signaling pathways may be implicated in ECM accumulation in certain conditions. In particular, STAT3 activation and an impairment of the BMP-SMAD1 signaling axis is thought to contribute to lung ECM accumulation. Based on the finding that transient pulmonary overexpression of OSM induces lung ECM accumulation in C57Bl/6 mice, it was hypothesized that OSM-induced ECM remodeling would be associated with STAT3 activation and suppression of the BMP-SMAD1-signaling axis.</p> <p>Findings in this thesis revealed that transient pulmonary overexpression of OSM induces ECM remodeling in both BALB/c and C57Bl/6 mice after seven days, despite a dichotomous response in other experimental models of ECM remodeling. However, parenchyma, but not airway, pathology resolved after 28 days in AdOSM-treated BALB/c mice. Furthermore, OSM-induced ECM remodeling occurred independently of IL-6-associated inflammation as well as TGF-β/SMAD3 signaling. MLF cultures treated with OSM did not directly regulate gene expression of ECM-related genes, suggesting that other cells may be responsible for OSM-induced ECM accumulation <em>in vivo</em>. OSM overexpression <em>in vivo </em>was associated with STAT3 activation and SMAD1 suppression, and an assessment of STAT3 and SMAD signaling <em>in vitro</em> showed that OSM activated the STAT3 pathway in MLF cultures, mouse type two pneumocytes, and human airway cells, while OSM suppressed the SMAD1 pathway in mouse type two pneumocytes, and human airway cells. Collectively, this thesis shows that OSM induces novel pathways in models of lung ECM remodeling, and this may have implications for IPF pathogenesis.</p> / Master of Science (MSc)

A remodelação do epitélio e do mesênquima subjacente tem um papel crucial na patogênese da fibrose pulmonar experimental. A iniciação, gravidade e distribuição de fibrose varia entre os diferentes agentes químicos. Estudos recentes indicaram que o envolvimento epitelial, a expressão de proteínas reguladoras do epitélio, ativação endotelial, estresse do retículo endoplasmático, a ativação de fibroblastos e acumulação de diferentes tipos de colágeno, pode ser específica em lesão causadas por diferentes agentes químicos. Neste estudo, comparou-se a fibrose pulmonar induzida por bleomicina (BLM) e hidroxitolueno butilado (BHT). Envolvimento epitelial, proteínas reguladoras, ativação endotelial e de fibroblastos foram quantitativamente avaliados pela densidade de células alveolares, expressão de telomerase, endotelina-1 (ET-1), fator de crescimento vascular (VEGF), fator de transformação do crescimento beta (TGF-beta) e do fator de crescimento de fibroblastos básico (bFGF). Estresse celular em células epiteliais alveolares do tipo 2 (AEC II) e fibroblastos, eventualmente, responsáveis pela gênese da fibrose pulmonar, foram investigados por microscopia eletrônica. Os colágenos do tipo I (Col I), III (Col III) e V (Col V) foram caracterizados e quantificados por imunofluorescência. A quantidade de colágeno pulmonar e alterações histológicas fibróticas foram significativamente aumentadas nos grupos BLM e BHT em relação aos controles, com diferença significativa entre a resposta fibrótica precoce e tardia. A densidade AEC II, a expressão da telomerase, ET-1, VEGF, TGF-beta e bFGF foram significativamente maiores nos grupos BLM e BHT do que em pulmões dos grupos controles, com diferença significativa entre a fase precoce e tardia da resposta fibrótica. Mitocôndrias anormais e estresse do retículo endoplasmático em AEC II e fibroblastos foram encontrados em ambos os grupos fibróticos. Aumento no acumulo de fibras de Col I, III e V, foram encontradas no interstício pulmonar após instilação de BLM e BHT. A expressão gênica de TGF-beta1 e alfa actina de músculo liso (alfa-SMA) foi significativamente maior em ambos modelos de fibrose pulmonar. Ativação de Smad3 (Mothers against decapentaplegic homolog 3) associada à expressão de IL-beta1 (Interleucina-1 beta), Lox (lisil-oxidase) e o fator de transcrição Sp1 (Specificity protein 1) foi associada com a ativação do gene alfa-SMA. Em conclusão, os nossos resultados tornam-se relevantes pois demonstram que, independentemente do insulto inicial, há uma convergência no perfil de sinalização, onde fica evidente que a lesão epitélio/endotelial está envolvida num amplo e contínuo processo de reparação com consequente final fibrótico. Um elemento chave no reparo e remodelamento tecidual ou fibrose é a resposta mesenquimal que fornece componentes essenciais de MEC necessários para a infraestrutura da cura e por outro lado para a fibrose progressiva crônica / Epithelial and underlying mesenchyme remodeling have a critical role in the pathogenesis of experimental pulmonary fibrosis. The initiation, distribution and severity of fibrosis varies among different chemical agents. Recent studies have indicated that epithelial involvement, expression of epithelial regulatory proteins, endothelium activation, endoplasmic reticulum stress, fibroblast activation and accumulation of different types of collagen may be specific in various chemical agents of injury. In this study, bleomycin (BLM) and Butylated hydroxytoluene (BHT)-induced pulmonary fibrosis in mice were compared. Epithelial involvement, regulatory proteins, endothelium and fibroblast activation were quantitatively evaluated by alveolar cells density, telomerase, endothelin-1 (ET-1), Vascular endothelial growth factor (VEGF), Transforming growth factor beta (TGF-beta) and basic fibroblast growth factor (bFGF) expression. Cellular stress in type 2 alveolar epithelial cells (AEC II) and fibroblasts, eventually responsible by generating lung fibrosis, were investigated by electron microscopy. We characterized and quantified collagen type I (Col I), III (Col III) and V (Col V) by immunofluorescence. Lung collagen content and fibrotic histological changes were significantly increased in BLM and BHT models compared to control with significant difference between early and late fibrotic response. AEC II density, telomerase expression, ET-1, VEGF, TGF-beta and bFGF were significantly higher than control lungs with significant difference between early and late BLM and BHT fibrotic response. Abnormal mitochondria and endoplasmic reticulum in AEC II and fibroblasts was found in both groups of chemical agents. Increased of Col I, Col III and V fibers accumulation was found in the lung interstitium after BLM and BHT instillation. The expression of TGF-beta1 and alfa smooth muscle actin (alfa-SMA) gene was significantly increased in both model of pulmonary fibrosis. Activated Smad3 (Mothers against decapentaplegic homolog 3) associated to the IL-beta1 (Interleukin-1 beta), Lox (Lysyl oxidase) and the transcription factor Sp1 (Specificity protein 1) was associated to the activation of alfa-SMA gene. In conclusion, our results become relevant because they demonstrate that, regardless of the initial insult, there is a convergence in the signaling profile, where it is clear that the epithelial/endothelial injury is involved in a broad and continuous repair process with consequent fibrotic end. A key component in tissue repair and remodeling, or fibrosis is the mesenchymal response which provides essential components of extracellular matrix infrastructure needed to cure and secondly for chronic progressive fibrosis

A remodelação do epitélio e do mesênquima subjacente tem um papel crucial na patogênese da fibrose pulmonar experimental. A iniciação, gravidade e distribuição de fibrose varia entre os diferentes agentes químicos. Estudos recentes indicaram que o envolvimento epitelial, a expressão de proteínas reguladoras do epitélio, ativação endotelial, estresse do retículo endoplasmático, a ativação de fibroblastos e acumulação de diferentes tipos de colágeno, pode ser específica em lesão causadas por diferentes agentes químicos. Neste estudo, comparou-se a fibrose pulmonar induzida por bleomicina (BLM) e hidroxitolueno butilado (BHT). Envolvimento epitelial, proteínas reguladoras, ativação endotelial e de fibroblastos foram quantitativamente avaliados pela densidade de células alveolares, expressão de telomerase, endotelina-1 (ET-1), fator de crescimento vascular (VEGF), fator de transformação do crescimento beta (TGF-beta) e do fator de crescimento de fibroblastos básico (bFGF). Estresse celular em células epiteliais alveolares do tipo 2 (AEC II) e fibroblastos, eventualmente, responsáveis pela gênese da fibrose pulmonar, foram investigados por microscopia eletrônica. Os colágenos do tipo I (Col I), III (Col III) e V (Col V) foram caracterizados e quantificados por imunofluorescência. A quantidade de colágeno pulmonar e alterações histológicas fibróticas foram significativamente aumentadas nos grupos BLM e BHT em relação aos controles, com diferença significativa entre a resposta fibrótica precoce e tardia. A densidade AEC II, a expressão da telomerase, ET-1, VEGF, TGF-beta e bFGF foram significativamente maiores nos grupos BLM e BHT do que em pulmões dos grupos controles, com diferença significativa entre a fase precoce e tardia da resposta fibrótica. Mitocôndrias anormais e estresse do retículo endoplasmático em AEC II e fibroblastos foram encontrados em ambos os grupos fibróticos. Aumento no acumulo de fibras de Col I, III e V, foram encontradas no interstício pulmonar após instilação de BLM e BHT. A expressão gênica de TGF-beta1 e alfa actina de músculo liso (alfa-SMA) foi significativamente maior em ambos modelos de fibrose pulmonar. Ativação de Smad3 (Mothers against decapentaplegic homolog 3) associada à expressão de IL-beta1 (Interleucina-1 beta), Lox (lisil-oxidase) e o fator de transcrição Sp1 (Specificity protein 1) foi associada com a ativação do gene alfa-SMA. Em conclusão, os nossos resultados tornam-se relevantes pois demonstram que, independentemente do insulto inicial, há uma convergência no perfil de sinalização, onde fica evidente que a lesão epitélio/endotelial está envolvida num amplo e contínuo processo de reparação com consequente final fibrótico. Um elemento chave no reparo e remodelamento tecidual ou fibrose é a resposta mesenquimal que fornece componentes essenciais de MEC necessários para a infraestrutura da cura e por outro lado para a fibrose progressiva crônica / Epithelial and underlying mesenchyme remodeling have a critical role in the pathogenesis of experimental pulmonary fibrosis. The initiation, distribution and severity of fibrosis varies among different chemical agents. Recent studies have indicated that epithelial involvement, expression of epithelial regulatory proteins, endothelium activation, endoplasmic reticulum stress, fibroblast activation and accumulation of different types of collagen may be specific in various chemical agents of injury. In this study, bleomycin (BLM) and Butylated hydroxytoluene (BHT)-induced pulmonary fibrosis in mice were compared. Epithelial involvement, regulatory proteins, endothelium and fibroblast activation were quantitatively evaluated by alveolar cells density, telomerase, endothelin-1 (ET-1), Vascular endothelial growth factor (VEGF), Transforming growth factor beta (TGF-beta) and basic fibroblast growth factor (bFGF) expression. Cellular stress in type 2 alveolar epithelial cells (AEC II) and fibroblasts, eventually responsible by generating lung fibrosis, were investigated by electron microscopy. We characterized and quantified collagen type I (Col I), III (Col III) and V (Col V) by immunofluorescence. Lung collagen content and fibrotic histological changes were significantly increased in BLM and BHT models compared to control with significant difference between early and late fibrotic response. AEC II density, telomerase expression, ET-1, VEGF, TGF-beta and bFGF were significantly higher than control lungs with significant difference between early and late BLM and BHT fibrotic response. Abnormal mitochondria and endoplasmic reticulum in AEC II and fibroblasts was found in both groups of chemical agents. Increased of Col I, Col III and V fibers accumulation was found in the lung interstitium after BLM and BHT instillation. The expression of TGF-beta1 and alfa smooth muscle actin (alfa-SMA) gene was significantly increased in both model of pulmonary fibrosis. Activated Smad3 (Mothers against decapentaplegic homolog 3) associated to the IL-beta1 (Interleukin-1 beta), Lox (Lysyl oxidase) and the transcription factor Sp1 (Specificity protein 1) was associated to the activation of alfa-SMA gene. In conclusion, our results become relevant because they demonstrate that, regardless of the initial insult, there is a convergence in the signaling profile, where it is clear that the epithelial/endothelial injury is involved in a broad and continuous repair process with consequent fibrotic end. A key component in tissue repair and remodeling, or fibrosis is the mesenchymal response which provides essential components of extracellular matrix infrastructure needed to cure and secondly for chronic progressive fibrosis